AMAG Pharmaceuticals’s Buy Rating Reaffirmed at Summer Street (AMAG)
AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “buy” rating reaffirmed by investment analysts at Summer Street in a note issued to investors on Thursday, Analyst Ratings Net reports. They currently have a $43.00 price target on the stock, up from their previous price target of $31.00. Summer Street’s price objective would indicate a potential upside of 87.12% from the stock’s previous close.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 5.05% during mid-day trading on Thursday, hitting $24.14. 134,767 shares of the company’s stock traded hands. AMAG Pharmaceuticals has a one year low of $13.85 and a one year high of $25.67. The stock has a 50-day moving average of $23.65 and a 200-day moving average of $22.22. The company’s market cap is $523.5 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, October 17th. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.12) by $0.11. The company had revenue of $21.60 million for the quarter, compared to the consensus estimate of $20.37 million. During the same quarter in the prior year, the company posted ($0.19) earnings per share. The company’s quarterly revenue was up 21.8% on a year-over-year basis. On average, analysts predict that AMAG Pharmaceuticals will post $-0.51 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on AMAG. Analysts at Robert W. Baird upgraded shares of AMAG Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, October 18th. They now have a $26.00 price target on the stock, up previously from $25.00. Separately, analysts at Zacks upgraded shares of AMAG Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 16th. They now have a $21.10 price target on the stock. Finally, analysts at Ladenburg Thalmann cut their price target on shares of AMAG Pharmaceuticals from $27.00 to $25.00 in a research note to investors on Monday, September 30th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. AMAG Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $24.73.
AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.